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Introduction
Plant materials have long been used as traditional medicines to treat various ailments and diseases. Traditional medicines attract much interest due to their ability to inhibit inflammation, platelet aggregation, thrombosis, ischemia of myocardium, cancer, etc. [1] [2] [3] [4] [5] [6] P-selectin (sP-selectin). The increase of sP-selectin levels in blood is one of the downstream events of in vivo platelet aggregation and thrombosis, and, consequently, the downregulation of sP-selectin is considered a possible target of both anti-inflammatory and antithrombotic agents. [16] [17] [18] [19] [20] [21] In this study, we hypothesized that AERL is capable of inhibiting the formation of thrombus and we investigated the in vitro antiplatelet aggregation, in vivo antithrombotic activity, in vitro inhibition of P-selectin, and nanofeatures of AERL. In addition, we docked the five nucleotides, four diterpenoids, and 21 phenolic acids of AERL into the active site of P-selectin to explore the antithrombotic ingredient.
Materials and methods Preparing aerl
Dry R. rubescens leaves (from Jiyuan, People's Republic of China; Dr Jingcheng Tang was responsible for the proper identification of R. rubescens and R. rubescens leaves) were ground and sifted through a 0.45 mm sieve in order to get fine powder. In a 50 mL Erlenmeyer flask, 0.5 g of powder was suspended in 10 mL of redistilled water. The suspension was stirred by using the same procedure for soaking tea, ie, stirring the suspension at 80°C for 30 minutes, then centrifuged (10 minutes, 2,000× g), filtered through a 0.45 μm microporous membrane, and evaporated under reduced pressure (40°C) to get 0.15 g of AERL as light yellow solids.
hPlc-PDa analysis
The HPLC-PDA analysis was performed on a Waters 2695 HPLC system with a Waters 2996 PDA. The HPLC column was a Kromasil C 18 (Dikma, Lake Forest, CA, USA) reversed-phase column (5 μm, 250 mm ×4.6 mm) protected by a guard column of the same material (5 μm, 10 mm ×4.6 mm). The column thermostat was maintained at 40°C. Onto the column, 50 μL of sample solution was injected for analysis. The mobile phase consisted of solvent A (spectroscopically pure acetonitrile; Beijing Chemical Works, Beijing, People's Republic of China), solvent B (0.05% [v/v] acetic acid; Beijing Chemical Works), and solvent C (0.5% [v/v] acetic acid in water; Beijing Chemical Works). The gradient elution program was described previously. 15 The flow rate of the mobile phase was 0.3 mL/min. After each run, the column was washed with acetonitrile and equilibrated to initial conditions for 15 minutes. UV absorption 3D spectra were recorded online. The PDA detector was set to a scanning range from 200 nm to 400 nm.
animals
Male Wistar rats were purchased from the Laboratory Animal Center of Capital Medical University (Beijing, People's Republic of China). The described assessments were based on a protocol (number: AEEI-2014-050) reviewed and approved by the Ethics Committee of Capital Medical University. The rats (weighing 250-300 g) were housed in polypropylene cages at 22°C±2°C and relative humidity of 60%-70%, with an automatically controlled 12/12-hour light/dark cycle, and provided with the standard pellet diet and drinking water in plastic bottles. All assays were conducted between 9 am and 4 pm. An overnight fast was imposed before assays.
In vitro antiplatelet aggregation assay
A two-channel Chronolog aggregometer was used to evaluate platelet aggregation. The platelet count was determined with an H-10 cell counter. Pig blood containing 3.8% sodium citrate (1:9 v/v, citrate:blood; purchased from the Laboratory Animal Center of Capital Medical University) was centrifuged at 100× g for 10 minutes, and the platelet-rich plasma (PRP) was collected. The remaining blood was centrifuged for an additional 10 minutes at 1,500× g to prepare platelet-poor plasma. The final platelet count of the PRP was adjusted to 2×10 8 platelets/mL with autologous platelet-poor plasma. Into an optical aggregometry testing tube, 0.5 mL of the adjusted plasma sample and 5 μL of normal saline (NS), 5 μL of the solution of aspirin (Sigma-Aldrich Co., St Louis, MO, USA) in NS (positive control, in a series of final concentrations of 1, 0.1, 0.01, 0.001, and 0.0001 mg/mL), or 5 μL of the solution of AERL in NS (in a series of final concentrations of 100, 10, 1, 0.1, 0.01, and 0.001 mg/mL) was added. After adjustment of the baseline, 5 μL of the solution of platelet-activating factor (PAF) (Sigma-Aldrich Co.) (final concentration 0.1 μM, prepared with NS), 5 μL of the solution of adenosine diphosphate (ADP) (Sigma-Aldrich Co.) (final concentration 10 μM, prepared with NS), 5 μL of the solution of arachidonic acid (AA) (Sigma-Aldrich Co.) (final concentration 350 μM, prepared with 1 M sodium carbonate), or 50 μL of the solution of thrombin (TH) (Sigma-Aldrich Co.) (final concentration 0.1 U/mL, prepared with NS) was added, and aggregation was recorded at 37°C for 5 minutes. The effect of AERL on PAF-, ADP-, AA-, or TH-induced platelet aggregation was observed in sextuple tubes. The maximum platelet aggregation (A m ) of NS, aspirin in NS, or AERL in NS was represented by the peak height of the aggregation curve (equal to the maximum light transmission). The inhibition rate was calculated according to the following formula: 
In vivo antithrombotic assay
Male Wistar rats weighing 250-300 g were used in this assay. Aspirin (positive control) and AERL were dissolved in NS before administration and kept in an ice bath. Thirty minutes after the oral administration of 3 mL/kg of NS (negative control), 3 mL/kg of aspirin in NS (positive control, 3 mg/kg and 30 mg/kg doses), 3 mL/kg of AERL in NS (50 mg/kg, 25 mg/kg, and 5 mg/kg doses), or 3 mL/kg of the antithrombotic ingredient in NS (25 mg/kg, 5 mg/kg, and 0.5 mg/kg doses), the rats were anesthetized with pentobarbital sodium (Beijing Pharmaceutical Works) (80.0 mg/kg, intraperitoneal) and the right carotid artery and left jugular vein were separated. A weighted 6 cm thread was inserted into the middle of a polyethylene tube which was filled with heparin sodium (50 IU/mL, in NS). One end of the polyethylene tube was inserted into the left jugular vein. From the other end of the polyethylene tube, heparin sodium was injected as anticoagulant, and this end was inserted into the right carotid artery. Blood was allowed to flow from the right carotid artery to the left jugular vein through the polyethylene tube for 15 minutes. The thread was retrieved to obtain the thrombus weight. After operation, the treated rats were euthanized immediately by exsanguination from the right carotid artery under pentobarbital sodium anesthesia.
sP-selectin determination sP-selectin levels were measured on citrated rat blood samples by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions with a rat P-selectin ELISA kit (Cusabio Biotech Co, Wuhan, People's Republic of China). Rat blood was collected in a 3.8% sodium citrate solution (1:9 v/v) and immediately centrifuged at 160× g for 15 minutes to collect PRP. To prepare the PRP sample, 5 mL of the diluent (from the kit) was added to 5 mL of PRP. To prepare R. rubescens solutions (0.5 mg/mL, 5.0 mg/mL, and 50.0 mg/mL), AERL was dissolved in NS. For the test samples, to a 960 μL PRP sample, 20 μL of AERL in NS was added, followed by incubation at 37°C for 5 minutes, to which 20 μL of AA in NS (0.15 mg/mL) was added, followed by incubation at 37°C for 3 minutes. For the blank control sample, to a 960 μL PRP sample, 20 μL of NS was added, followed by incubation at 37°C for 5 minutes, after which 20 μL of AA in NS (0.15 mg/mL) was added, followed by incubation at 37°C for another 3 minutes. To the test wells and the control wells of a 96-well plate coated with the enzyme, 100 μL of AERL-treated PRP sample and 100 μL of NS-treated PRP sample were added, respectively. After incubation at 37°C for 120 minutes and removal of the solvent, 100 μL of the biotin labeled antibody (from the kit) was added to each well. The plate was incubated at 37°C for 60 minutes, and the solvent was removed. After washing with washing solution (from the kit) three times, 100 μL of horseradish peroxidase labeled avidin (from the kit) was added to each well, the plate was incubated at 37°C for another 60 minutes, and the solvent was removed again. After washing with washing solution (from the kit) five times, 90 μL of the substrate (from the kit) was added to each well, gently mixed, and protected from light for 20 minutes at 37°C for coloration. To each well, 50 μL of the stop solution (from the kit) was added to stop coloration. The optical density value of each well was recorded at 450 nm and the sP-selectin level was determined according to the standard samples (from the kit). 22 
Flow cytometry assay
Rat blood was collected in an aqueous solution of 3.8% sodium citrate (1:9 v/v) and immediately centrifuged at 160× g for 15 minutes to get PRP. To 500 μL of PRP, 10 μL of the antithrombotic ingredient in NS (final concentration, 0.1 μM) was added, and the mixture was incubated at 37°C for 30 minutes, to which 10 μL of AA in NS (0.15 mg/mL) was added. The system was incubated at 37°C for 5 minutes and centrifuged at 500× g for 10 minutes to precipitate the platelets. The precipitated platelets were then stained with PE-anti-CD62P (Shanghai XingYou Biological Technology Co., Ltd, Shanghai, People's Republic of China) for 20 minutes. PE fluorescence, for gated platelet populations, was analyzed for ~30,000 events (counts) per sample aliquot and fluorescence data were recorded accordingly. The level of platelet activation was assessed by the fluorescence height of P-selectin.
Transmission electron microscopy images
The characterization of the nanoimage of the lyophilized solids of AERL in water was identified by transmission electron microscopy (TEM) (JSM-6360 LV; JEOL, Tokyo, Japan). The solution of AERL in ultrapure water (1.0, 0.5, 0.25, and 0.12 mg/mL) was dripped onto a carbon-coated Formvar copper grid and then a drop of anhydrous ethanol was added in order to assist the removal of water. The grid was dried thoroughly in air, and the TEM image was tested at an 80 kV electron beam accelerating voltage. The nanoimages were recorded on an imaging plate (Gatan Bioscan camera model 1792) with 20 eV energy windows at 6,000-400,000×. The TEM image was obtained from counting over 100 species in a randomly selected region. The images were digitally enlarged. All determinations were carried out in triplicate grids.
atomic force microscopy images
Atomic force microscopy (AFM) images were obtained using the contact mode on a Nanoscope 3D AFM (Veeco Instruments, Inc., Plainview, NY, USA) under ambient conditions. Samples of AERL in rat plasma (0.5 mg/mL) and rat plasma alone were used for recording the images.
Molecular docking
In the molecular docking, the structure of P-selectin was treated as rigid and prepared by AutoDockTools 1.5, ie, merging nonpolar hydrogens and assigning Gasteiger charges and AutoDock elements. Then, the energy-minimized 3D conformations of the five nucleotides, 21 phenolic acids, and four diterpenoids of AERL were treated as flexible and prepared by AutoDockTools 1.5, ie, merging nonpolar hydrogens, assigning Gasteiger charges, finding root and aromatic carbons, detecting rotatable bonds, and setting torsions. The grid box dimensions were set to 22.5 Å ×30 Å ×30 Å using a grid spacing of 0.375 Å for two average structures.
To determine the probable binding conformations, AutoDock 4, a very popular docking program with a high success rate, the energy-minimized 3D conformations of the five nucleotides, 21 phenolic acids, and four diterpenoids of AERL were used to dock into the active sites of the average structure of P-selectin. This allows automated docking of flexible ligands to a rigid receptor with certain flexible residues. The residues within 4 Å of SLeX and PSGL-1 in crystal structures were the residue set of Tyr45, Ser46, Ser47, Arg85, His108, Lys111, Lys112, and His114 and the residue set of Tyr48, Lys84, Arg85, Glu88, Glu92, Tyr94, Ser99, and Glu107, respectively, as well as Ca 2+ coordinating residue set of Glu80, Asn82, Asn105, and Asp106. The residues of the active pockets of the average structure should be limited in these residues. Lamarckian genetic algorithm was used to find the appropriate binding positions, orientations, and conformations of the five nucleotides, 21 phenolic acids, and four diterpenoids of AERL in the binding site of the average structure. The global optimization was started with parameters of a population of 100 randomly positioned individuals. The maximum number of energy evaluations was increased to 2.5×10 7 and the maximum number of generations in the Lamarckian genetic algorithm was increased to 2.7×10 5 . The Solis and Wets local search was performed with a maximum number of 3,000. During each simulation experiment, 256 runs were carried out for each of the AERL ingredients. The resulting 256 conformations of the five nucleotides, 21 phenolic acids, and four diterpenoids were scored by the lowest binding energy and clustered using a root mean square tolerance of 2.0 Å.
statistical analysis
Data analysis was performed using an ANOVA test. A P-value less than 0.05 was considered as statistically significant.
Results
aerl selectively inhibits platelet aggregation in vitro
The in vitro antiplatelet aggregation assay was performed, and the IC 50 values are shown in Figure 1 . The IC 50 values of AERL against TH-, AA-, ADP-, and PAF-induced platelet aggregation were 0.12 mg/mL, 0.24 mg/mL, 1.24 mg/mL, and 1.43 mg/mL, respectively. In respect of the sensitivity to AERL, the IC 50 value of AERL against TH-induced platelet aggregation was significantly lower than those of AERL against AA-, ADP-, and PAF-induced platelet aggregation. Therefore, AERL selectively inhibits TH-induced platelet aggregation.
aerl dose-dependently inhibits rats from forming thrombus in vivo
Thrombus weights were measured in the rat model, and the data are shown in Figure 2 . The thrombus weights of the rats orally receiving 25 mg/kg and 50 mg/kg of AERL were significantly lower than that of the rats orally receiving NS, while the thrombus weight of the rats orally receiving 5 mg/kg of AERL was equal to that of the rats orally receiving NS. On the other hand, when the dose increased from 5 mg/kg to 25 mg/kg and 50 mg/kg, the thrombus weight gradually decreased. These data demonstrate that AERL can prevent thrombus formation in a dose-dependent manner, and the minimal effective dose is 25 mg/kg. aerl concentration-dependently inhibits platelets to release P-selectin in vitro
To determine the effect of AERL on platelets releasing sP-selectin, NS and 3S-tetrahydroisoquinoline-3-carboxylic acid (IQCA) (a known P-selectin inhibitor 23 ) were used as the blank and positive controls, respectively. The concentrations of sP-selectin released from AA-activated platelets treated with NS, IQCA, and AERL were measured, and the results are shown in Figure 3 . As can be seen, the levels of sP-selectin from the platelets treated with 0.1 mM of IQCA and 0.1 mg/mL and 1.0 mg/mL of AERL were significantly lower than that of sP-selectin from the platelets treated with
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The actions of aqueous extract of Rabdosia rubescens leaves NS, while the level of sP-selectin from the platelets treated with 0.01 mg/mL of AERL was equal to that of sP-selectin from the platelets treated with NS. These data demonstrate that AERL can downregulate platelet sP-selectin release in a concentration-dependent manner.
In water, aerl forms nanoparticles
To show the nanoimage of the lyophilized solids of AERL in water, a TEM test was performed. Using the standard procedure, the nanofeatures of various concentrations of AERL were defined and are shown in Figure 4A -D and Figure S3 . Figure 4A indicates that 1.0 mg/mL of AERL formed nanoparticles of 4.5-63.6 nm in diameter. Figure 4B indicates that 0.5 mg/mL of AERL formed nanoparticles of 32.9-180.8 nm in diameter. Figure 4C indicates that 0.25 mg/mL of AERL formed nanoparticles of 38.9-227.8 nm in diameter. Figure 4D indicates that 0.12 mg/mL of AERL formed nanoparticles of 45.7-234.3 nm in diameter. These data show that, with the concentration decreases from 1.0 mg/mL to 0.12 mg/mL, the diameter of the nanoparticles progressively increased.
In rat plasma, aerl forms nanoparticles
To show the nanoimage of the lyophilized solids of AERL dissolved in rat plasma, an AFM test was performed. Using the standard procedure, the nanofeature of the 0.5 mg/mL solution of AERL in plasma was defined and is shown in Figure 4E . Figure 4F , the AFM image of plasma alone, indicates that in plasma alone, no interesting nanospecies were formed. Figure 4E indicates that, in rat plasma, 0.5 mg/mL of AERL formed nanoparticles of 53-159 nm in diameter. Therefore, in rat plasma, AERL forms nanoparticles.
The docking feature of rosmarinic acid in P-selectin's active site
To address the antithrombotic ingredient of AERL, dockingbased screening was performed. In brief, five nucleotides, 21 phenolic acids, and four diterpenoids of AERL, 15 of which the HPLC-PDA 3D chromatogram is shown in Figure 5 and Table S1 , were docked into the active site of P-selectin. The docking demonstrated that rosmarinic acid had the lowest energy and could be assigned as the antithrombotic 
rosmarinic acid downregulates P-selectin expression
According to the docking investigation, rosmarinic acid, the main ingredient of AERL, was tested in flow cytometry analysis. 24, 25 The structure is identified by NME spectra, in Figure S1 and Figure S2 . Figure 6 shows that, in vitro, 0.1 μM ingredient of AERL. The docking feature of rosmarinic acid in P-selectin's active site was defined by the interactions of the hydroxyl and carboxyl of rosmarinic acid with the amino acid residues of the active site and is shown in 
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Wang et al of rosmarinic acid effectively downregulated AA-activated rat platelet P-selectin expression. The fluorescence intensities of unlabeled platelets (background), PE-anti-CD62P-labeled platelets (normal reference), PE-anti-CD62P-labeled and AA-activated platelets without rosmarinic acid (positive control), and PE-anti-CD62P-labeled and AA-activated platelets with 1 μM of rosmarinic acid were 17, 102, 167, and 105, respectively. This indicates that the P-selectin level significantly decreased in the presence of 1 μM of rosmarinic acid.
rosmarinic acid inhibits thrombosis in vivo
According to the flow cytometry analysis, 25, 5, and 0.5 mg/kg of rosmarinic acid were tested in the in vivo antithrombotic assay, and the data are shown in Figure 2B . The thrombus weights of the rats orally receiving 25 and 5 mg/kg of rosmarinic acid were significantly lower than that of the rats orally receiving NS, while the thrombus weight of the rats orally receiving 0.5 mg/kg of rosmarinic acid was equal to that of the rats orally receiving NS. On the other hand, when the dose increased from 0.5 mg/kg to 5 mg/kg or 25 mg/kg, the thrombus weight dose-dependently decreased. Thus, rosmarinic acid has the capability of preventing thrombus formation in rats, with a minimal effective dose of 5 mg/kg.
Discussion
Using the preparation procedure described in the "Materials and methods" section, AERL was obtained in a good yield and had good solubility. Besides, this aqueous extract gave the same chromatogram ( Figure 5B ) of HPLC-PDA previously reported. 15 The yield, solubility, and composition of the extract demonstrate that this procedure is suitable for preparing AERL. The IC 50 values in Figure 1 not only indicate AERL can effectively inhibit platelet aggregation in vitro, but also show that the potency of AERL inhibiting platelet aggregation induced by TH was twofold, tenfold, and 12-fold higher than that of AERL inhibiting platelet aggregation induced by AA, ADP, and PAF, respectively, and that AERL therefore selectively inhibits TH-induced platelet aggregation. Figure 2A demonstrates the effective oral dose of AERL inhibiting the in vivo thrombosis was 25 mg/kg (6.3 mg per rat). Taking the IC 50 values of AERL against platelet aggregation into account, the effective oral dose of 25 mg/kg supports an interpretation that oral AERL could be sufficiently absorbed in vivo. Since a 250 g rat maximally has 16 mL of blood, at a 25 mg/kg dose, the blood concentration should at least reach 6.3 mg/16 mL (0.4 mg/mL), which is 3.3-, 1.7-, 0.3-, or 0.3-fold of 0.12 mg/mL, 0.24 mg/mL, 1.24 mg/mL, or 1.43 mg/mL (the IC 50 s mentioned above), respectively. This correlation between IC 50 and effective dose indicates that TH and AA could be mainly responsible for the in vivo antithrombotic action, and implies that only a few of the ingredients possess in vitro antiplatelet aggregation and in vivo antithrombotic actions.
As a glycoprotein, P-selectin is normally stored in platelet α-granules. Upon activation, P-selectin mobilizes to the surface membrane of the activated platelets, is shed from the platelet surface to form sP-selectin, and is released into the bloodstream.
26-29 The increase of circulation concentration of sP-selectin plays a core role in thrombosis, and inhibition of sP-selectin production has been considered one of the principal mechanisms of antithrombotic agents. Therefore, Figure 3 depicts concentration dependence of AERL inhibiting AA-activated platelets from releasing sP-selectin and discloses a possible mechanism of action of AERL offering in vitro antiplatelet aggregation and in vivo antithrombotic action.
The TEM nanoimages of Figure 4 indicate that AERL concentration-dependently forms nanoparticles. The nanoparticles formed by 1.0 mg/mL of AERL had the smallest diameter range (4.5-63.6 nm) and the maximum blood concentration of the rats receiving 50 mg/kg of AERL was ~1.0 mg/mL. The AFM nanoimages of rat plasma alone ( Figure 4F ) indicate no interesting nanospecies, while Figure 4E indicates that, in rat plasma, 0.5 mg/mL of AERL formed nanoparticles of 53-159 nm in diameter, and the diameter of most nanoparticles was less than 100 nm. It is accepted that the particles with a diameter lower than 100 nm cannot be trapped by macrophages, 30 and it is understandable that 50 mg/kg of AERL has desirable in vivo antithrombotic activity.
Through docking of five nucleotides, 21 phenolic acids, and four diterpenoids ( Figure 5B ) into the active site of P-selectin, rosmarinic acid was proved to be the antithrombotic ingredient of AERL. Figure 5A depicts the docking feature of rosmarinic acid in the active site, defines the hydrogen bonds between the hydroxyl and carboxyl of rosmarinic acid with the principle amino acid residues of the active site of P-selectin, and predicts the possibility of rosmarinic acid being the antithrombotic ingredient of AERL.
The flow cytometry analysis depicted in Figure 6 indicated that 0.1 μM of rosmarinic acid could effectively downregulate AA-activated rat platelets to express sPselectin. This in vitro data support the docking-based prediction that rosmarinic acid would be one of the antithrombotic ingredients of AERL. Figure 2B 
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The actions of aqueous extract of Rabdosia rubescens leaves of rosmarinic acid in blocking thrombosis, suggesting that the in vivo data also support a prediction that rosmarinic acid is one of the antithrombotic ingredients of AERL.
Conclusion
AERL concentration-dependently inhibits in vitro platelet aggregation induced by TH, AA, ADP, and PAF and selectively inhibits in vitro platelet aggregation induced by TH. In a rat model, oral AERL dose-dependently inhibited thrombosis. Both the in vitro antiplatelet aggregation and the in vivo antithrombotic action were the result of AERL inhibiting AA-activated platelets from releasing sP-selectin. In water, AERL concentration-dependently forms nanoparticles. The nanoparticles formed in 1.0 mg/mL of aqueous AERL had a small size and benefited both the in vitro adhesion and the in vivo delivery. The docking-based screening of the five nucleotides, 21 phenolic acids, and four diterpenoids identified by HPLC-PDA/(-)ESI-MS/MS analysis predicted that rosmarinic acid was the antithrombotic ingredient of AERL, which was confirmed by flow cytometry assay and rat model-based in vivo antithrombotic assay. Figure S3 . As can be seen, when 0.5 mg/mL or 15 mg/mL of AERL was irradiated with a 650 nm laser beam, the Faraday-Tyndall effect clearly occurred. In addition, the zeta potential and particle size of AERL were determined on a Malvern Zetasizer (Nano ZS90; Malvern Instruments, Malvern, UK) with the DTS (Nano) program and are shown in Figure S3D and E. 
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Figure S2
13 c NMr of rosmarinic acid. Notes: 13 
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